CN101153042A - 噻吩并嘧啶化合物及其用途 - Google Patents

噻吩并嘧啶化合物及其用途 Download PDF

Info

Publication number
CN101153042A
CN101153042A CNA2007101869688A CN200710186968A CN101153042A CN 101153042 A CN101153042 A CN 101153042A CN A2007101869688 A CNA2007101869688 A CN A2007101869688A CN 200710186968 A CN200710186968 A CN 200710186968A CN 101153042 A CN101153042 A CN 101153042A
Authority
CN
China
Prior art keywords
methyl
alkyl
compound
unsubstituted
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007101869688A
Other languages
English (en)
Chinese (zh)
Inventor
长展生
今田岐
飞高武宪
三轮宪弘
日下雅美
铃木伸宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CN101153042A publication Critical patent/CN101153042A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2007101869688A 2003-01-29 2004-01-28 噻吩并嘧啶化合物及其用途 Pending CN101153042A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP020854/03 2003-01-29
JP2003020854 2003-01-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800087989A Division CN100360538C (zh) 2003-01-29 2004-01-28 噻吩并嘧啶化合物及其用途

Publications (1)

Publication Number Publication Date
CN101153042A true CN101153042A (zh) 2008-04-02

Family

ID=32820637

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2007101869688A Pending CN101153042A (zh) 2003-01-29 2004-01-28 噻吩并嘧啶化合物及其用途
CNB2004800087989A Expired - Lifetime CN100360538C (zh) 2003-01-29 2004-01-28 噻吩并嘧啶化合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB2004800087989A Expired - Lifetime CN100360538C (zh) 2003-01-29 2004-01-28 噻吩并嘧啶化合物及其用途

Country Status (26)

Country Link
US (4) US7300935B2 (https=)
EP (1) EP1591446B1 (https=)
KR (1) KR101074462B1 (https=)
CN (2) CN101153042A (https=)
AU (1) AU2004207706B2 (https=)
BE (1) BE2022C501I2 (https=)
BR (1) BRPI0407082C1 (https=)
CA (1) CA2514407C (https=)
CO (1) CO5590921A2 (https=)
CY (2) CY1114008T1 (https=)
DK (1) DK1591446T3 (https=)
ES (1) ES2410814T3 (https=)
FR (1) FR21C1056I2 (https=)
HU (1) HUS2100052I1 (https=)
IL (1) IL169869A (https=)
LT (1) LTC1591446I2 (https=)
MX (1) MXPA05007990A (https=)
NL (1) NL301158I2 (https=)
NO (2) NO331981B1 (https=)
NZ (1) NZ541772A (https=)
PL (1) PL214756B1 (https=)
PT (1) PT1591446E (https=)
RU (1) RU2331648C2 (https=)
SI (1) SI1591446T1 (https=)
WO (1) WO2004067535A1 (https=)
ZA (1) ZA200506611B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021031148A1 (zh) * 2019-08-21 2021-02-25 深圳仁泰医药科技有限公司 促性腺素释放激素拮抗剂的晶型及其制备方法和用途
CN114174302A (zh) * 2019-08-02 2022-03-11 庄信万丰股份有限公司 瑞卢戈利的固态形式
CN114989134A (zh) * 2022-07-14 2022-09-02 江西同和药业股份有限公司 一种噻吩类化合物及其制备方法与应用
CN116589399A (zh) * 2023-05-29 2023-08-15 济南大学 一种3-甲氧基-2-硝基吡啶的制备方法

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
KR20080041662A (ko) 2005-07-22 2008-05-13 다케다 야쿠힌 고교 가부시키가이샤 조기 배란 예방제
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
EP2329823A4 (en) * 2008-09-03 2013-04-03 Takeda Pharmaceutical PROCESS FOR INCREASING THE ABSORPTION ABILITY OF A PREPARATION AND PREPARATION WITH INCREASED ABSORPTION ABILITY
EA024252B1 (ru) * 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
WO2011153050A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
WO2012135571A1 (en) 2011-04-01 2012-10-04 Curis, Inc. Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
RS57157B1 (sr) * 2011-11-11 2018-07-31 Gilead Apollo Llc Acc inhibitori i njihove primene
PL2900675T3 (pl) 2012-09-28 2019-08-30 Takeda Pharmaceutical Company Limited Sposób wytwarzania pochodnej tienopirymidyny
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
EP2881391A1 (en) 2013-12-05 2015-06-10 Bayer Pharma Aktiengesellschaft Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof
CA2978223A1 (en) * 2015-02-26 2016-09-01 Takeda Pharmaceutical Company Limited Formulations of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethyl amino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
ES2882255T3 (es) 2015-07-01 2021-12-01 California Inst Of Techn Sistemas de administración basados en polímeros de ácido múcico catiónicos
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
PL3380479T3 (pl) 2015-11-25 2023-05-08 Gilead Apollo, Llc Triazolowe inhibitory acc i ich zastosowania
BR112018009212B1 (pt) 2015-11-25 2022-06-14 Gilead Apollo, Llc Método para controlar patógenos fúngicos agrícolas
EA201890949A1 (ru) 2015-11-25 2018-12-28 Джилид Аполло, Ллс СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
AU2016361412A1 (en) 2015-11-25 2018-05-24 Gilead Apollo, Llc Pyrazole ACC inhibitors and uses thereof
RU2610281C1 (ru) * 2016-02-26 2017-02-08 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ НАУКИ ИНСТИТУТ ОРГАНИЧЕСКОЙ ХИМИИ им. Н.Д. ЗЕЛИНСКОГО РОССИЙСКОЙ АКАДЕМИИ НАУК (ИОХ РАН) Способ получения 2-фтор-3-метилбут-2-ениламина или его гидрохлорида (Варианты)
SG11201807077RA (en) 2016-03-02 2018-09-27 Gilead Apollo Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
CN110248661A (zh) 2016-09-30 2019-09-17 梦欧文科学有限责任公司 前列腺癌的治疗
EP3518933B2 (en) 2016-09-30 2025-02-26 Sumitomo Pharma Switzerland GmbH Methods of treating uterine fibroids and endometriosis
SI4122464T1 (sl) 2017-03-28 2024-07-31 Gilead Sciences, Inc. Terapevtske kombinacije za zdravljenje bolezni jeter
SG11201911598WA (en) 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
WO2019178304A1 (en) * 2018-03-14 2019-09-19 Teva Pharmaceuticals International Gmbh Solid state forms of relugolix
US12441738B2 (en) 2018-03-14 2025-10-14 Assia Chemical Industries Ltd. Solid state forms of Relugolix
WO2019241327A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
CN113164466B (zh) 2018-09-11 2025-07-08 柯瑞斯公司 使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗
CA3117092A1 (en) 2018-10-29 2020-05-07 ObsEva S.A. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
SG11202104053TA (en) 2018-11-07 2021-05-28 ObsEva SA Compositions and methods for the treatment of estrogen-dependent disorders
EP3666776A1 (en) * 2018-12-11 2020-06-17 Sandoz AG Hydrate of a gonadotropin-releasing hormone receptor antagonist
WO2020230094A1 (en) * 2019-05-15 2020-11-19 Dr. Reddy’S Laboratories Limited Amorphous and crystalline forms of relugolix
CN110194776B (zh) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 一种瑞卢戈利的合成方法
CN111943960B (zh) * 2019-07-29 2022-02-15 广东东阳光药业有限公司 取代的嘧啶二酮类化合物及其用途
CN112321602A (zh) * 2019-08-05 2021-02-05 苏州鹏旭医药科技有限公司 一种瑞卢戈利药物中间体的制备方法
AU2020325655B2 (en) 2019-08-08 2025-09-11 Kissei Pharmaceutical Co., Ltd. Compositions and methods for the treatment of estrogen-dependent disorders
AU2020325721A1 (en) 2019-08-08 2022-03-03 ObsEva S.A. GnRH antagonists for the treatment of estrogen-dependent disorders
CN112390812A (zh) * 2019-08-14 2021-02-23 苏州鹏旭医药科技有限公司 瑞卢戈利化合物的晶型和无定型固体及其制备方法
EP4041738A1 (en) * 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
JP2022551316A (ja) * 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
CN112745304A (zh) * 2019-10-29 2021-05-04 上海度德医药科技有限公司 一种Relugolix的制备方法及中间体化合物
CN113444105A (zh) * 2020-03-27 2021-09-28 南京海润医药有限公司 一种Relugolix的制备方法
CN111333633B (zh) * 2020-04-01 2023-10-20 江西科睿药业有限公司 一种瑞卢戈利的中间体化合物及其制备方法和用途
CN111574534B (zh) * 2020-05-25 2021-06-04 东莞市东阳光新药研发有限公司 苯基取代的噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮类化合物及其用途
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
CN111793078B (zh) * 2020-07-03 2022-02-01 东莞市东阳光新药研发有限公司 双环含氮杂芳基取代的嘧啶二酮类化合物及其用途
CN111875614B (zh) * 2020-07-03 2022-04-29 东莞市东阳光新药研发有限公司 杂环基取代的噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮类化合物及其用途
CN111909168B (zh) * 2020-07-31 2022-02-01 广东东阳光药业有限公司 含氮杂环基取代的嘧啶二酮类化合物及其用途
CN111925379B (zh) * 2020-07-31 2022-02-15 广东东阳光药业有限公司 含氮杂芳基取代的嘧啶二酮类化合物及其用途
CN113754679B (zh) * 2020-09-09 2023-04-07 广东东阳光药业有限公司 取代的嘧啶二酮类化合物及其用途
CN112047957B (zh) * 2020-09-09 2022-02-01 广东东阳光药业有限公司 取代的嘧啶二酮类化合物及其用途
CN112142757B (zh) * 2020-09-29 2022-02-15 广东东阳光药业有限公司 五元含氮杂芳基取代的嘧啶二酮类化合物及其用途
EP4243829A1 (en) 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
CN112552312B (zh) * 2020-12-07 2022-08-05 杭州科巢生物科技有限公司 一种瑞卢戈利或其盐的合成方法
CN113620972A (zh) * 2021-02-02 2021-11-09 奥锐特药业(天津)有限公司 瑞卢戈利新晶型及其制备方法
CN114907370B (zh) 2021-02-10 2023-11-03 奥锐特药业(天津)有限公司 高纯度的噻吩并嘧啶化合物及其制备方法
CN115073491A (zh) * 2021-03-12 2022-09-20 上海医药工业研究院 一种瑞卢戈利中间体、其制备方法及其应用
WO2022214645A1 (en) 2021-04-09 2022-10-13 Farmhispania Group, S.L. Processes and intermediates for the preparation of relugolix
CN113135934A (zh) * 2021-04-28 2021-07-20 北京海美源医药科技有限公司 用于制备瑞卢戈利的中间体化合物及其制备方法和瑞卢戈利的制备方法
CN115260211B (zh) * 2021-04-29 2024-02-06 长春金赛药业有限责任公司 含噻吩稠环类衍生物、药物组合物及其制备方法和应用
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
WO2023072284A1 (zh) * 2021-11-01 2023-05-04 山东绿叶制药有限公司 促性腺素释放激素拮抗剂及其制备方法和应用
CN114230576A (zh) * 2021-12-21 2022-03-25 伊诺药物研究(南京)有限公司 一种瑞卢戈利的制备方法
CN115417883B (zh) * 2022-09-16 2024-08-27 浙江科聚生物医药有限公司 一种瑞卢戈利的晶型及其制备方法
EP4634195A1 (en) 2022-12-15 2025-10-22 Medichem, S.A. Process for the preparation of relugolix
EP4703363A1 (en) * 2023-04-27 2026-03-04 Shandong Luye Pharmaceutical Co., Ltd. Salt form and crystal form of thienopyrimidine compound, and preparation method therefor and use thereof
CN121202886A (zh) * 2024-06-26 2025-12-26 浙江养生堂天然药物研究所有限公司 杂环类化合物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048863A (en) 1994-04-19 2000-04-11 Takeda Chemical Industries, Ltd. Condensed-ring thiophene derivatives and thienopyrimidine derivatives, their production and use
UY23948A1 (es) * 1995-02-08 2001-10-25 Takeda Chemical Industries Ltd Derivados de anillos condensados de tiofeno su producción y uso.
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
RU2233284C2 (ru) * 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
KR20030005205A (ko) 2000-02-29 2003-01-17 다케다 야쿠힌 고교 가부시키가이샤 티에노피리미딘 유도체의 제조 방법
JP2001316391A (ja) * 2000-02-29 2001-11-13 Takeda Chem Ind Ltd チエノピリミジン誘導体の製造法
US20030134863A1 (en) 2000-04-13 2003-07-17 Shuichi Furuya Preventives/remedies for alzheimer's disease
JP2001354588A (ja) * 2000-04-13 2001-12-25 Takeda Chem Ind Ltd アルツハイマー病予防・治療剤
EP1291023A1 (en) 2000-06-14 2003-03-12 Takeda Chemical Industries, Ltd. Sustained release compositions
JP2002068982A (ja) * 2000-06-14 2002-03-08 Takeda Chem Ind Ltd 徐放性組成物
JP2002080397A (ja) * 2000-07-05 2002-03-19 Takeda Chem Ind Ltd 性ホルモン依存性疾患の治療用医薬製剤
US20030176360A1 (en) 2000-07-05 2003-09-18 Yasutaka Igari Medicinal preparations for treating sex hormone-dependent diseases
AU2001288102A1 (en) 2000-09-22 2002-04-02 Takeda Chemical Industries Ltd. Solid preparations
JP2002167327A (ja) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd 固形製剤
WO2002043766A1 (en) * 2000-11-29 2002-06-06 Takeda Chemical Industries, Ltd. Medicinal compositions and process for producing the same
AU2002221139A1 (en) 2000-12-15 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof
EP1370562A1 (en) 2001-02-14 2003-12-17 Warner-Lambert Company LLC Thieno[2,3-d]pyrimidindione derivatives as matrix metalloproteinase inhibitors
JP5072166B2 (ja) * 2002-01-30 2012-11-14 武田薬品工業株式会社 チエノピリミジン化合物、その製造法および用途
US7569570B2 (en) 2002-01-30 2009-08-04 Takeda Pharmaceutical Company Limited Thienopyrimidines, process for preparing the same and use thereof
AU2003211877A1 (en) 2002-03-11 2003-09-22 Takeda Chemical Industries, Ltd. Remedies for sex hormone-dependent disease
JP2004002321A (ja) * 2002-03-11 2004-01-08 Takeda Chem Ind Ltd 性ホルモン依存性疾患治療剤
EP1495768A4 (en) 2002-04-12 2007-12-05 Takeda Pharmaceutical MEANS FOR THE PREVENTION / TREATMENT OF HITZEWALLUNGEN
JP2004002377A (ja) * 2002-04-12 2004-01-08 Takeda Chem Ind Ltd ホットフラッシュ予防・治療剤

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114174302A (zh) * 2019-08-02 2022-03-11 庄信万丰股份有限公司 瑞卢戈利的固态形式
WO2021031148A1 (zh) * 2019-08-21 2021-02-25 深圳仁泰医药科技有限公司 促性腺素释放激素拮抗剂的晶型及其制备方法和用途
US12497409B2 (en) 2019-08-21 2025-12-16 Shenzhen Jingtai Technology Co., Ltd. Crystal form of gonadotropin releasing hormone antagonist, preparation method therefor, and use thereof
CN114989134A (zh) * 2022-07-14 2022-09-02 江西同和药业股份有限公司 一种噻吩类化合物及其制备方法与应用
CN114989134B (zh) * 2022-07-14 2023-11-14 江西同和药业股份有限公司 一种噻吩类化合物及其制备方法与应用
CN116589399A (zh) * 2023-05-29 2023-08-15 济南大学 一种3-甲氧基-2-硝基吡啶的制备方法

Also Published As

Publication number Publication date
KR20050096171A (ko) 2005-10-05
US20060160829A1 (en) 2006-07-20
LTC1591446I2 (https=) 2023-04-25
EP1591446A4 (en) 2008-04-30
BRPI0407082B8 (pt) 2019-06-25
IL169869A (en) 2011-10-31
WO2004067535A1 (ja) 2004-08-12
CY2021039I2 (el) 2022-03-24
US20080108623A1 (en) 2008-05-08
CA2514407C (en) 2012-01-03
ZA200506611B (en) 2006-12-27
PT1591446E (pt) 2013-06-12
NO2021052I1 (no) 2021-12-16
US8735401B2 (en) 2014-05-27
CA2514407A1 (en) 2004-08-12
NO331981B1 (no) 2012-05-21
PL378002A1 (pl) 2006-02-20
US9346822B2 (en) 2016-05-24
CY2021039I1 (el) 2022-03-24
MXPA05007990A (es) 2005-09-20
CN100360538C (zh) 2008-01-09
BE2022C501I2 (https=) 2023-03-07
FR21C1056I2 (fr) 2022-11-18
HK1084665A1 (en) 2006-08-04
AU2004207706B2 (en) 2010-03-04
BRPI0407082C1 (pt) 2021-05-25
CY1114008T1 (el) 2016-07-27
ES2410814T3 (es) 2013-07-03
RU2331648C2 (ru) 2008-08-20
CO5590921A2 (es) 2005-12-30
CN1768065A (zh) 2006-05-03
LTPA2021529I1 (https=) 2021-12-10
FR21C1056I1 (https=) 2022-01-21
US8058280B2 (en) 2011-11-15
NO20053974L (no) 2005-10-27
PL214756B1 (pl) 2013-09-30
HUS2100052I1 (hu) 2021-12-28
DK1591446T3 (da) 2013-06-10
US20140221381A1 (en) 2014-08-07
BRPI0407082B1 (pt) 2019-06-04
AU2004207706A1 (en) 2004-08-12
NZ541772A (en) 2009-10-30
NO20053974D0 (no) 2005-08-25
US20120071486A1 (en) 2012-03-22
BRPI0407082A (pt) 2006-01-24
RU2005127052A (ru) 2006-02-10
SI1591446T1 (sl) 2013-07-31
EP1591446A1 (en) 2005-11-02
NL301158I2 (nl) 2022-05-25
KR101074462B1 (ko) 2011-10-18
EP1591446B1 (en) 2013-03-06
US7300935B2 (en) 2007-11-27

Similar Documents

Publication Publication Date Title
CN100360538C (zh) 噻吩并嘧啶化合物及其用途
CN107857755B (zh) 作为trka激酶抑制剂的n-吡咯烷基、n′-吡唑基-脲、硫脲、胍和氰基胍化合物
CN100439340C (zh) 作为蛋白激酶抑制剂的3-氰基喹啉、3-氰基-1,6-二氮杂萘和3-氰基-1,7-二氮杂萘
CN110582495B (zh) 作为tnf活性的调节剂的稠合五环咪唑衍生物
CN110964008B (zh) 取代吡唑稠环类衍生物及其制备方法和应用
CN103974948B (zh) 在治疗过度增殖性疾病中用作bub1激酶抑制剂的取代的苄基吲唑
CN104011051B (zh) 通过fgfr激酶抑制抗癌的吡啶并吡嗪
CN104024233B (zh) 通过fgfr激酶的抑制抗癌的苯并吡嗪类化合物
CN103153300A (zh) 杂芳基化合物和其用途
CN101229164B (zh) 含氮杂吲哚氧代乙酰哌嗪衍生物的药物制剂
CN102858765A (zh) 吡唑基喹唑啉激酶抑制剂
CN113637007A (zh) Rho激酶抑制剂
CN103421005A (zh) 具有抗肿瘤活性的乙炔衍生物
CN101842357A (zh) 取代的吡唑衍生物
CN102887891A (zh) N4-苯基-喹唑啉-4-胺衍生物和相关化合物
CN105130967A (zh) 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物
CN101541751A (zh) 喹啉化合物
TW201713663A (zh) 經雜芳基取代之胺基吡啶化合物
JP4039574B2 (ja) チエノピリミジン化合物およびその用途
HK40062730A (en) Rho kinase inhibitors
HK40062731A (en) Rho kinase inhibitors
HK40064586A (en) Rho kinase inhibitors
HK40062732A (en) Rho kinase inhibitors
CN121889390A (zh) 能够用于治疗smarca4缺失型癌症的作为smarca2抑制剂的1,6-萘啶化合物
HK1243417B (zh) 吡啶酮和氮杂吡啶酮化合物及使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20080402